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Abstract
Background: We assessed how the diagnosis of Celiac Disease (CD) is made and how the new ESPGHAN guidelines
can be applied in children from countries with different resources.
Methods: A real life prospective study was performed in 14 centres of 13 different Mediterranean countries.
Participants were asked to apply the usual diagnostic work-up for CD according to their diagnostic facilities.
Results: There were 1974 patients enrolled in the study, mean age 4 years, 10 months; 865 male, 1109 female. CD was
confirmed in 511 (25.9%) and was unconfirmed in 1391 (70.5%) patients; 14 patients were diagnosed as having
CD according to the new ESPGHAN guidelines, 43 patients were classified as having potential CD. In all participating
countries the diagnosis of CD relied on histology of duodenal biopsy; in 5 countries, HLA, and in one country
endomysial antibodies (EMA) were not available. Symptoms did not add a significant increase to the pre-test
probability of serological tests. The positive predictive value of tissue transglutaminase type 2 (tTG) antibodies
performed with different kits but all corresponding to those recommended by ESPGHAN was 96.1% (95% CI
94–97.9%) in presence of tTG > 10xULN. In 135 patients with tTG >10xULN, HLA genotyping was performed
and in all it was compatible with CD.
Conclusions: The results of our study show that CD diagnosis still relies on intestinal biopsy in the Mediterranean
area. New ESPGHAN criteria are not applicable in 5 countries due to lack of resources needed to perform
HLA genotyping and, in one country, EMA assay. Further simplification of the new ESPGHAN guidelines might
be made according to what preliminarily the present results suggest if confirmed by new prospective studies.
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Background
Prevalence of celiac disease (CD) has been estimated at
around 1% in Western populations [1] but most patients
remain undiagnosed. The burden of unrecognized CD in
countries with poor resources and facilities for diagnosis is
very heavy [2]. Factors influencing the onset of this non
communicable epidemics have been taken into consider-
ation also recently [3–8]. New ESPGHAN guidelines [9]
state that the protocol for the diagnosis of CD changed as
a result of the availability of CD-specific tissue transgluta-
minase type 2 antibodies (tTG). As in children and adoles-
cents with signs or symptoms suggestive of CD and high
tTG titers with levels >10 times Upper Limits of Normal
(ULN), the likelihood of villous atrophy (Marsh type 3) is
very high, it has been suggested [9] that histological as-
sessment may be omitted in symptomatic patients in
whom these high tTG levels are verified by endomysial
antibodies (EMA) positivity and are HLA-DQ2 and/or
HLA-DQ8 heterodimer positive.
However ESPGHAN states that it is necessary to per-
form prospective research studies.
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After the publication of the new ESPGHAN criteria,
apart from a large study investigating antibody diagnos-
tics in paediatric CD [10], 2 prospective studies [11, 12]
have been performed to our knowledge. One other pro-
spective study adopted criteria other than those sug-
gested by the guidelines [13].
Two main problems should be highlighted:
- there are many different tTG antibody tests;
- new ESPGHAN criteria were applied in some studies,
but these studies have been performed, with only one
exception [12], in tertiary centres of affluent countries
in subjects with classical gastrointestinal disease.
Therefore, the conclusions of a recent commentary on
the applicability of the new ESPGHAN Guidelines for
diagnosing CD in children from resource limited coun-
tries [14] rely on a single centre prospective study com-
prising only 142 children.
The Mediterranean Network for the Management of
Food-Induced Diseases (MEDICEL) is a EUROMED-
based action in which Mediterranean countries with dif-
ferent resources and diagnostic facilities participate. It,
therefore, represents the real life ideal setting in which the
new ESPGHAN guidelines can be prospectively applied.
The objectives of this prospective study were to assess
how the diagnosis of CD is made in different countries
and how the new ESPGHAN guidelines can be applied
in different Mediterranean countries.
Methods
Study design
A real life prospective study was performed in 14 centres
of 13 different Mediterranean countries participating to
the MEDICEL network; all unselected new cases referred
to these Centres for suspected CD and asymptomatic sub-
jects with autoimmune CD-associated diseases or familiar-
ity for CD were enrolled, from April 2013 to July 2014.
Participants were asked to apply the usual diagnostic
work-up for CD according to their diagnostic facilities
and to classify enrolled subjects as confirmed or uncon-
firmed CD according to shared criteria, as done in their
usual clinical practice. Two sessions of shared agreement
on diagnostic criteria were run through the MEDICEL
network before starting the study.
Criteria for admission were: age below 18 years,
clinical signs and symptoms of CD (systemic, gastrointes-
tinal, extraintestinal) and/or associated autoimmune
diseases (type 1 diabetes mellitus, thyroiditis, other
autoimmune diseases) and/or no symptoms but famil-
iarity for CD (1st and 2nd degree).
Criteria for exclusion were: already known diagnoses
of CD only.
Familiarity, associated diseases, clinical symptoms,
tTG as N x Upper Limit Normal (ULN), EMA, histology
(Marsh-Oberhuber classification) [15], were collected
into the database.
HLA-DQ2/DQ8 and follow-up were performed to
confirm uncertain cases.
Diagnostic procedures
The tTG, EMA and HLA typing methods utilized by the
Centres participating in the study, if available, are shown
in Table 1.
tTG were determined with a kit of the 14 most fre-
quently applied serum anti-TG2 IgA antibody assays taken
in consideration in the new ESPGHAN guidelines (9).
Table 1 tTG, EMA and HLA typing methods utilized by the Centres participating in the study
Country tTG kit EMA substrate HLA typing kit
Albania Orgentec Monkey esophagus NA
Algeria Phadia - EliA Celikey Monkey esophagus NA
Croatia Phadia - EliA Celikey Monkey esophagus Tepnel LIfecodes Corporation
Egypt Euroimmun NA NA
Greece Inova Monkey esophagus Olerup, HLA typing kits
Italy (ME) Euroimmun Umbilical cord BioDiagene - DQ-CD Typing Plus kit
Italy (NA) Eurospital Monkey esophagus BioDiagene - DQ-CD Typing Plus kit
Malta Orgentec Monkey esophagus Invitrogen / Life technologies
Montenegro Aesku Monkey esophagus Olerup, HLA typing kits
Morocco Orgentec Monkey esophagus NA
Slovenia Eurospital Monkey esophagus Olerup, HLA typing kits
Spain Celikey; Pharmacia & Upjohn Monkey esophagus Tepnel LIfecodes Corporation
Tunisia Inova Monkey esophagus NA
Turkey Orgentec Monkey esophagus Olerup, HLA typing kits
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With the exception of 1 centre, that utilized umbilical
cord as substrate, all Centres assayed EMA on monkey
esophagus as substrate.
In each Centre at least 4 endoscopic biopsy samples
from duodenum, including one from bulbus, were taken.
Data provided by participants to the study were re-
evaluated by A.S., L.G. and G.M, and classified as shown
in Table 2.
Crosstabs and stepwise statistics were generated by
SPSS and t-Test, Relative Risk (RR) and Positive Predict-
ive Value (PPV) were estimated for each variable assum-
ing histology as the gold standard.
Results
Population
Demographic data of all the patients, and according to
the final diagnosis, are shown in Table 3.
There were 1974 patients enrolled in the study, mean
age 4 years, 10 months; 865 male, 1109 female. A global
view of the classification and investigations performed
by each Centre can be seen in the Flow Chart (Fig. 1)
and in Table 4. CD was confirmed (CCD) in 511 (25.9%)
and was unconfirmed (UCD) in 1391 (70.5%) patients.
Apart from 14 patients diagnosed as having CD according
to the new ESPGHAN guidelines (NCCD: New Criteria
Celiac Disease), 2.47% of the final amount of diagnoses of
CD, 43 patients were classified as having Potential Celiac
Disease (PCD), 7.4% of the CD population, and 16 defined
as having “high probability” of CD, as EMA or HLA were
positive, but not both were done.
Symptoms
The proportion of asymptomatic cases enrolled for fa-
miliarity and of symptoms in CCD and UCD are
shown in Table 5. A higher prevalence of asymptom-
atic cases, food refusal, globose abdomen and paleness
was found in CCD, whereas abdominal pain and con-
stipation were more common in the UCD. No differ-
ence was found for diarrhoea and failure to thrive
between the two groups.
Diagnostic tools
Table 4 shows the frequency of various investigations
performed in different countries: in 5 countries, HLA,
and in one EMA assays were not available. HLA was not
performed in Malta because it was not considered
necessary.
Serology
In 91 patients, tTG antibodies were not performed; out
of these, 7 patients showed positivity for EMA and hist-
ology, allowing to classify them as CCD, while in the
other 84 cases CD was excluded (thus, they were classi-
fied as UCD, see Fig. 1). Of 1883 patients evaluated for
tTG: 1219 were negative, while 664 were positive.
Among the 1307 UCD patients in whom tTG were per-
formed, 1215 resulted negative, while 92 resulted positive:
70/1307 (5.4%) had tTG titre higher than 2 x ULN, and
22/1307 (1.7%) had tTG titre higher than 10 x ULN.
Four patients received diagnosis of CD despite having
negative titre of tTG in presence of EMA positve: one was
classified as PCD because of Marsh type 0, while the other
3 presented a Marsh type equal to or higher than 2. tTG
sensitivity and specificity were 99.3% (95% CI 98.6-99.9%)
and 93% (95% CI 91.6-94.3%) respectively, with a RR
1888.53 (95% CI 690.61-5164.35) of being celiac.
Results of EMA assay are shown in Fig. 2. EMA sensi-
tivity and specificity were 99.5% (95% CI 98.8-100%) and
90.1% (95% CI 87.5-92.7%) respectively.
Both EMA and tTG were performed in 464 patients
who underwent intestinal biopsy as well: 66 were
EMA negative and 398 EMA positive. The reliability
of tTG versus EMA is defined by its sensitivity 95.7%
(95% CI 93.86-97.54%) and specificity 95.8% (95% CI
93.91-97.69%). High titers of tTG > 10 x ULN were
found in 427 patients, out of whom EMA were per-
formed in 289 and were found absent in only 3 pa-
tients (1.04%). Intestinal biopsy was performed in 2 of
these latter patients and in both, histology showed a
Marsh type 3c confirming CD diagnosis. The third
was classified as UCD because of having done neither
HLA nor intestinal biopsy.
Table 2 Classification of the patients’ diagnoses
Classification Histology tTG EMA HLA
CCDa ≥ Marsh type 2 Positive or not done Positive or not done Positive or not done
NCCD Not done >10 x ULN Positive Positive
UCD Not done or Marsh type 0-1 <5 x ULN Negative Not done
PCD Marsh 0-1 Positive Positive Positive
High probability CDb Not done >10 x ULN Positive or not done Positive or not done
CD Celiac Disease, CCD Confirmed Celiac Disease, NCCD New Criteria Celiac Disease, UCD Unconfirmed Celiac Disease, PCD Potential Celiac Disease, tTg tissue
transglutaminase type 2 antibodies, EMA endomysial antibodies, ULN Upper Limit of Normal
aat least tTG or EMA positive or both positive; bEMA or HLA positive but not both done. This category was not taken into account for comparison of the variables
considered in the study
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In 135 patients with tTG > 10 x ULN, HLA geno-
typing was performed and in all of them it was com-
patible with CD.
Out of the 413 patients with tTG > 10 x ULN (exclud-
ing 14 patients diagnosed according to the new ESP-
GHAN criteria) both EMA and HLA were performed in
88. In all these patients a duodenal biopsy was per-
formed, and in 85/88 the diagnosis would have been cor-
rectly made according to the new criteria; in 3 (3.41%)
the diagnosis of PCD would have been missed in ab-
sence of the biopsy.
Biopsy was performed in 382 out of the 427 patients
with high titre tTG, and histology showed at least a
Marsh type 2 in 367 patients (96.1%). Thus, in this sub-
group of patients, the positive predictive value of tTG >
10 x ULN was 96.1% (95% CI 94-97.9%).
Biopsy
Of 1974 cases included in this study, 1002 underwent an
intestinal biopsy and in 542 at least Marsh type 2 muco-
sal damage was found: 511 (94%) were classified as
CCD, because of positivity of tTG or EMA, 31 (6%) were
classified as UCD because of negativity of both tTG and
EMA.
Out of 460 patients with Marsh type 0-1, 42 (9%) were
classified as PCD in light of the positivity of EMA or
tTG antibodies. In particular, 8 of them had tTG > 10 x
ULN, 6 between 5 and 10 x ULN, 27 between 1 and 5 x
ULN. One patient had a negative titre of tTG (0.9 x
ULN), but he was symptomatic (abdominal pain) and
had positive EMA with compatible HLA.
In 364/460 with a Marsh type 0-1 at biopsy, no anti-
bodies were produced and they were classified as UCD.
Overall, 568 patients were diagnosed as having CD (in-
cluding CCD, NCCD and PCD), 2.47% of whom accord-
ing to the new guidelines.
The presence of high titre of tTG correlates with vil-
lous atrophy (Fig. 3).
HLA
Less than 20% (382) of the total number of enrolled pa-
tients underwent a HLA analysis: in 63, that were both
DQ2 and DQ8 negative, CD was finally excluded they
were classified as UCD.
Table 3 Demographic data according to the final diagnosis
No. (%) Gender (F/M) Age (M ± SD)
PATIENTS 1974 1109/865 4.83 ± 4.72
Confirmed 511 (25.9%) 320/191 4.1 ± 4.11
Unconfirmed 1391 (70.5%) 739/652 5.11 ± 4.89
Potential 42 (2.1%) 28/14 4.25 ± 4.51
Diagnosed according new ESPGHAN guidelines 14 (0.7%) 10/4 3.97 ± 3.59
High probability 16 (0.8%) 12/4 2.98 ± 2.93
Fig. 1 Prospective study design. Detailed legend: tTG: tissue transglutaminase; CD: celiac disease; CCD: confirmed celiac disease; UCD:
unconfirmed celiac disease; PCD: potential celiac disease; NCCD: celiac disease diagnosed according to new EPSGHAN criteria; M: Marsh degree
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Associated diseases
About 80% of the total study population had no other dis-
ease. The significant differences in prevalence of associated
diseases in UCD and CCD are shown in Table 6. The fre-
quency of thyroiditis, type 1 diabetes mellitus and derma-
titis herpetiformis was higher in CCD, whereas IgA
deficiency and hypertransaminasemia were higher in UCD.
Discussion
Our study, for the first time, provides a wide picture of
CD diagnosis feasibility in 13 Mediterranean countries
with different health resources and facilities. It is also
the largest one investigating antibody diagnostics in
paediatric CD that prospectively evaluates the new ESP-
GHAN guidelines in different countries including those
with poor resources.
In all participating countries, the diagnosis of CD re-
lied on histology of duodenal biopsy, but other diagnos-
tic procedures were not always available. In particular, in
5 countries, HLA, and in 1, EMA were not performed.
Even though HLA was not required when the diagnosis
was not in doubt, in some countries the limitation of
performing it derives from its cost. The same is true for
EMA assay.
On the other hand, in order to apply what is suggested
by the new ESPGHAN guidelines, apart from the pres-
ence of symptoms and high antibody levels, HLA has to
be compatible and EMA have to be present if the diag-
nosis of CD is to be made without a biopsy. In 4 centres,
the diagnosis of CD was made for a total of 14 patients
according to these new guidelines, omitting a duodenal
biopsy.
Even though CD can be reliably diagnosed following
the latest ESPGHAN and BSPGHAN guidelines [16], as
not all diagnostic procedures required by the new guide-
lines are available in all countries, our results may sug-
gest to further simplify the new ESPGHAN guidelines.
As a matter of fact, it is not useful nor necessary to per-
form an expensive determination, such as HLA, as in all
patients with tTG higher than 10 x ULN who had HLA
heterodimer determined it was compatible with CD.
Moreover EMA, which is not easily performed in all
countries, does not add diagnostic accuracy to tTG, as
Table 4 Distribution of patients by study centers and according to the final diagnosis and performed diagnostic investigations
Country N. Pts. N. CCD +
NCCDa





Albania 45 25 20 0 45 7 (1) 32 (25) 0
Algeria 71 17 54 0 70 6 (2) 54 (17) 0
Croatia 310 12 + 1 293 3 304 25 (6) 202 (12) 14
Egypt 200 5 195 0 159 0 21 (5) 0
Greece 46 35 10 1 46 40 (31) 46 (35) 27
Italy (ME) 332 111 199 15 307 273 (108) 142 (111) 13
Italy (NA) 339 152 + 9 153 17 330 281 (151) 202 (152) 109
Malta 27 14 13 0 26 16 (14) 27 (14) 0
Montenegro 18 11 4 2 17 5 (3) 16 (11) 11
Morocco 106 45 61 0 100 1 (1) 90 (45) 0
Slovenia 234 29 + 1 203 1 234 234 (29) 34 (29) 66
Spain 40 4 + 3 32 1 40 10 (4) 8 (4) 9
Tunisia 67 22 44 1 66 23 (11) 43 (22) 0
Turkey 139 29 109 1 139 5 (1) 85 (29) 133
TOTAL 1974 511 + 14 1391 42 1883 926 (362) 1002 (511) 382
N. Pts Number of Patients, N. CCD Number of Patients with Confirmed Celiac Disease, N. UCD Number of Patients with Unconfirmed Celiac Disease, N. PCD N. of
Patients with potential celiac disease, N. tTG Number of tissue TransGlutaminase antibody assays, N. EMA Number of EndoMysial Antibody assays
adiagnosed according to new ESPGHAN criteria omitting biopsy
Table 5 Distribution of symptoms in UCD and CCD patients
Symptoms UCD (%) CCD (%) χ2 p
No symptoms 93 (6.7%) 120 (20.6%) 82.4 <0.0001
Abdominal pain 402 (28.9%) 69 (11.8%) 65.9 <0.0001
Constipation 89 (6.4%) 17 (2.9%) 9.8 0.002
Diarrhea 297 (21.4%) 145 (24.9%) 2.93 0.087
Failure to thrive 266 (19.1%) 98 (16.8%) 1.46 0.227
Food refusal 16 (1.2%) 14 (2.4%) 4.3 0.038
Globose abdomen 29 (2.1%) 22 (3.8%) 4.66 0.031
Mood changes 5 (0.4%) 6 (1%) 3.33 0.068
Paleness 46 (3.3%) 31 (5.3%) 4.43 0.035
Vomiting 103 (7.4%) 30 (5.1%) 3.34 0.068
Others 45 (3.2%) 31 (5.3%) 4.81 0.028
UCD Unconfirmed Celiac Disease, CCD Confirmed Celiac Disease
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suggested by the cases in which both tests were per-
formed and tTG was > 10 x ULN. In 3 cases of our
study, in whom EMA were negative, histology showed
a picture that allowed us to make the diagnosis of
CD. Rather than determining EMA, in the presence
of such a high titre tTG, it is better to repeat a sec-
ond test for tTG according also to what is suggested
by the Joint BSPGHAN and Coeliac UK guidelines
for diagnosis and management of CD in children [17].
In a commentary regarding applicability of the new
ESPGHAN guidelines for diagnosing celiac disease in
children from resource limited countries [14], it has
been suggested that positive HLA-DQ2/DQ8 serotype
and EMA are necessary in order to apply the ESP-
GHAN guidelines for serological diagnosis of CD, and
that CD should not be diagnosed on the basis of a
single high tTG-titre. Our study comprising many
countries with limited resources suggests that both
HLA and EMA may be omitted and CD may be diag-
nosed on the basis of repeated high tTG titres.
Altogether, the diagnosis would have been correctly
made according to the new criteria in 85 out 88 pa-
tients with tTG > 10 x ULN who underwent tTG and
EMA determination, together with intestinal biopsy.
In 3 patients (3.41%), the diagnosis of PCD would
have been missed in absence of the biopsy.
Fig. 2 Role of EMA assay in the diagnosis. Detailed legend: *tTg and Histology positive
Fig. 3 Correlation among tTG titre and villous atrophy
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Thus, some practical issues need to be addressed. In
adopting the new ESPGHAN criteria, it has to be kept
in mind that there is a chance that patients might have a
potential CD. In a prospective cohort study [18], which
describes the long term natural history of potential CD
by a 9 years follow-up, the risk of becoming atrophic
was estimated at 18% especially in subjects with persist-
ent positive serology, while serology became negative in
20% of potential patients on follow up. Even if rarely, po-
tential celiac patients showed a TTG value >10 x ULN:
hence this limit does not exclude the chance of finding
potential celiac cases. Starting from this point, the deci-
sion to omit biopsy and the chance of being a potential
CD should be thoroughly discussed with families consid-
ering the life-long diagnosis of CD. The new ESPGHAN
guidelines also state that it is important to be precise in
the clinical evaluation of patients and to perform pro-
spective research studies. To the best of our knowledge,
our prospective study is the largest one including 511
(+14) CD patients and 1391 controls and it shows that
symptoms are not able to assign a pre-test probability to
serological tests. On the other hand, Webb et al. [11]
found no difference in terms of diagnostic accuracy of
tTG in asymptomatic children diagnosed as having CD
detected by screening.
We are aware of the limitations of our study, mostly
due to the unequal distribution of enrolled patients
across participating countries, although the total number
is the largest one reported.
Therefore, further prospective multicentre studies with
an homogeneous enrolment of patients should be
planned also in order to try a further simplification of
ESPGHAN guidelines.
Moreover, due to different test kinetics the 10 x UNL
is not the same with all tTG tests. However, all the cen-
tres participating in the study utilized one of the 14 most
frequently applied serum tTG assays in Europe taken in
consideration in the new ESPGHAN guidelines Appendix.
All these assays underwent United Kingdom National Ex-
ternal Quality Assessment according to which the 10 x
ULN was suggested by the new guidelines in order to omit
intestinal biopsy. Considering that all the centres took at
least 4 duodenal biopsy samples always including a sample
from the bulbus we are confident that histology is the
right gold standard chosen in this study.
Conclusions
This is the largest prospective study providing a wide
picture of CD diagnosis feasibility in Mediterranean
countries with different health resources and facilities.
The results of our study show that CD diagnosis still re-
lies on intestinal biopsy in the Mediterranean area. New
ESPGHAN criteria are not applicable in 5 countries due
to lack of resources needed to perform HLA genotyping
and, in one country, EMA assay. Further simplification
of the new ESPGHAN guidelines might be made accord-
ing to what preliminarily the present results suggest if
confirmed by new prospective studies. This would be a
result of great value especially for countries with limited
resources, even though the chance of a potential CD has
to be taken into account and discussed with the families
when intestinal biopsy is omitted.
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